Recommendation ID
IPG492/1
Question
NICE encourages further research into bioresorbable stent implantation for treating coronary artery disease and may review the procedure on publication of further evidence. Details of subsequent antiplatelet therapy should be reported and outcomes should include major adverse cardiac events (MACE) and target vessel revascularisation (defined as any repeat percutaneous intervention or surgical bypass of any segment of the treated vessel), particularly in the long term (at least 2–3 years). Studies on the safety and efficacy of the procedure compared with other types of coronary stent implantation would be useful.
Any explanatory notes
(if applicable)
Current evidence on the short-term safety and efficacy of bioresorbable stent implantation for treating coronary artery disease is adequate, but the quantity of evidence on the safety and efficacy of the procedure in the long term is inadequate. Therefore this procedure should only be used with special arrangements for clinical governance, consent and audit or research.

Source guidance details

Comes from guidance
Bioresorbable stent implantation for treating coronary artery disease
Number
IPG492
Date issued
May 2014

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 26/06/2014